Pradefovir

SKU: orb1699597

Description

Pradefovir (Remofovir) is a liver-targeted prodrug of adefovir developed for chronic hepatitis B virus (HBV) research. It is metabolically activated in the liver to the active reverse transcriptase inhibitor PMEA. This compound is utilized in both in vitro enzymatic studies and in vivo models of HBV infection to investigate targeted antiviral therapies.

Research Area

Infectious Disease & Virology, Metabolism Research

Key Properties

• CAS Number: 625095-60-5
• MW: 423.79
• Purity: 97.50% (May vary between batches)
• Formula: C₁₇H₁₉ClN₅O₄P
• SMILES: C(COCP1(=O)O[C@@H](CCO1)C2=CC(Cl)=CC=C2)N3C=4C(N=C3)=C(N)N=CN4
• Target: HBV,Cytochromes P450
• Solubility: DMSO:Soluble

Bioactivity

• In Vivo:
  Pradefovir, a prodrug of PMEA, is under phase 2 clinical trial in China to evaluate its pharmacokinetic and pharmacodynamics after multiple-dose study, with adefovir dipivoxil and tenofovir disoproxil fumarate as positive control. A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantification of pradefovir, PMEA and tenofovir in HBV patient serum. Serum samples were pretreated via simple protein precipitation with methanol and entecavir was used as internal standard. Chromatographic separation was carried out on a Synergi fusion-RP column (150mm×4.6mm) by gradient elution with methanol and 0.1% formic acid in water (v/v) at a flow rate of 1mL/min. The analytes were detected in multiple reaction monitoring mode with positive ion electrospray ionization at m/z 424.1/151.0, 274.1/162.2, 288.1/176.1, and 278.1/152.2for pradefovir, PMEA, tenofovir and IS, respectively. The assays were validated according to current bioanalytical guidelines including specificity, linearity (2.0-500ng/mL for pradefovir and PMEA, 4.0-1000ng/mL for tenofovir), accuracy and precision, extraction recovery, matrix effect and stability. The validated method has been successfully applied to the pharmacokinetic study of pradefovir, adefovir dipivoxil and tenofovir disoproxil fumarate in a set of HBV patients.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Pradefovir, Remofovir, MB6866, MB-6866, MB06866, MB-06866, MB 6866, MB 06866, HBV, ICN20013, ICN-20013, ICN-2001-3, ICN 20013

Compound Identifiers

PubChem CID

6451146